New blood test method improves prostate cancer screening

Researchers at the Karolinska Institute in Sweden recently reported that magnetic resonance imaging (MRI) can reduce overdiagnosis and improve prostate cancer screening
.

Now, the same research team has published a study on Lancet Oncology, which shows that adding a new blood test, the Stockholm 3 test, can reduce MRI imaging by one-third, while further preventing detection Mild, low-risk tumors

"In general, our research shows that we have identified the tools needed to perform effective and safe prostate cancer screening
.

Tobias Nordström, associate professor of urology, Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet Said, "After years of debate and research, it feels great to be able to come up with knowledge that can improve male healthcare

Current screening methods—PSA (Prostate Specific Antigen) testing combined with traditional biopsies—result in unnecessary biopsies and the discovery of a large number of small, low-risk tumors (overdiagnosis)
.

Therefore, apart from Lithuania, no country has chosen to implement a nationwide prostate cancer screening program because the advantages outweigh the disadvantages

On July 9, 2021, the results of the STHLM3MRI study were published in the New England Journal of Medicine, showing that magnetic resonance imaging (MRI) and targeted biopsy can be used to replace traditional prostate biopsy, thereby reducing overdiagnosis
.

The results of the new study published in The Lancet Oncology show that the Stockholm m3 detection method developed by researchers at Karolinska Institutet can be used as an important supplement

"The availability of magnetic resonance imaging in the medical field will be a limiting factor
.

We now prove that a new blood test as an auxiliary means of MRI can reduce the number of MRIs by one-third

STHLM3MRI is a randomized study conducted between 2018 and 2021, with a total of 12,750 male participants from Stockholm County
.

Participants provided an initial blood sample for PSA analysis and analysis using the new Stockholm m3 test

"It has been demonstrated previously that the use of the Stockholm 3 test and MRI alone is cost-effective.

Tobias Nordström concludes
.

Original search:

 ”Prostate cancer screening using a combination of risk-prediction, magnetic resonance imaging and targeted prostate biopsies: results from the population-based STHLM3MRI trial”.

T.